{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:53:57Z","timestamp":1758765237440,"version":"3.44.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1 DP2 DK124891-01","R01 MD016401-01"],"award-info":[{"award-number":["1 DP2 DK124891-01","R01 MD016401-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.kint.2023.04.022","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T11:09:04Z","timestamp":1684753744000},"page":"228-230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["APOL1 channel blocker reduces proteinuria in FSGS"],"prefix":"10.1016","volume":"104","author":[{"given":"Opeyemi A.","family":"Olabisi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2023.04.022_bib1","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2215\/CJN.15161219","article-title":"APOL1 nephropathy: from genetics to clinical applications","volume":"16","author":"Friedman","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"year":"2017","series-title":"2017 USRDS annual data report: epidemiology of kidney disease in the United States","key":"10.1016\/j.kint.2023.04.022_bib2"},{"key":"10.1016\/j.kint.2023.04.022_bib3","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/ng.232","article-title":"MYH9 is associated with nondiabetic end-stage renal disease in African Americans","volume":"40","author":"Kao","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.kint.2023.04.022_bib4","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/ng.226","article-title":"MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis","volume":"40","author":"Kopp","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.kint.2023.04.022_bib5","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1193032","article-title":"Association of trypanolytic ApoL1 variants with kidney disease in African Americans","volume":"329","author":"Genovese","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.kint.2023.04.022_bib6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00439-010-0861-0","article-title":"Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene","volume":"128","author":"Tzur","year":"2010","journal-title":"Hum Genet"},{"key":"10.1016\/j.kint.2023.04.022_bib7","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1073\/pnas.1522913113","article-title":"APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases","volume":"113","author":"Olabisi","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2023.04.022_bib8","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa2202396","article-title":"Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants","volume":"388","author":"Egbuna","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.04.022_bib9","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.157432","article-title":"JAK inhibitor blocks COVID-19 cytokine-induced JAK\/STAT\/APOL1 signaling in glomerular cells and podocytopathy in human kidney organoids","volume":"7","author":"Nystrom","year":"2022","journal-title":"JCI Insight"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253823003423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253823003423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:04:24Z","timestamp":1758762264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253823003423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0085253823003423"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2023.04.022","relation":{},"ISSN":["0085-2538"],"issn-type":[{"type":"print","value":"0085-2538"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"APOL1 channel blocker reduces proteinuria in FSGS","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2023.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}